Upcoming IPO: Paramesu Biotech Received Approval For ₹600 IPO

Paramesu Biotech Ltd has received a green signal from the capital market regulator, the Securities and Exchange Board of India (SEBI) to raise funds via an initial public offering (IPO).

Paramesu Biotech IPO Details

Paramesu Biotech IPO is a ₹600 crore public offering comprising a fresh issue of ₹520 crore and OFS ₹80 crore with the face value of ₹5 each share. Pantomath Capital Advisor Pvt Ltd is the lead manager of the IPO proceeds and Big Share Services Pvt Ltd is assigned as the registrar of this IPO. In the Paramesu IPO, QIB has a 50% allocation, 35% for retailers, and 15% for NII.

Use of IPO Proceeds

Paramesu Biotech Ltd has decided to use the proceeds raised from this upcoming IPO for the following:

• Debt Repayments
• General Corporate Purposes

About Paramesu Biotech Limited

Founded in 2011, Paramesu Biotech Limited (PBL) specialises in maize-based products and began its commercial operations in 2015 with a production capacity of 160 TPD. The company operates from a prominent production facility in Devarapalli, West Godavari District, Andhra Pradesh. PBL has successfully established a strong presence in both domestic and international markets.

Thanks to its diverse product range, solid market position, commitment to quality, and expanding production capabilities, Paramesu Biotech Ltd. has gained recognition nationally and internationally.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.